Attached files

file filename
EX-99.1 - EX-99.1 - CATALYST BIOSCIENCES, INC.cbio-ex991_49.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 8, 2017

 

CATALYST BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware

 

000-51173

 

56-2020050

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

 

 

 

 

260 Littlefield Ave.

South San Francisco, California

 

94080

(Address of principal executive offices)

 

(Zip Code)

(650) 266–8674

Registrant’s telephone number, including area code

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 


 

Item 2.02.

Results of Operations and Financial Condition.

On March 8, 2017, Catalyst Biosciences, Inc., a Delaware corporation (the “Company”), announced its fourth quarter 2016 financial results. A copy of the Company’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

No.

  

Description

 

 

 

99.1

 

Press release issued on March 8, 2017 by Catalyst Biosciences, Inc.

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

CATALYST BIOSCIENCES, INC.

 

 

 

 

Date: March 8, 2017

 

 

/s/ Nassim Usman

 

 

 

Nassim Usman, Ph.D.

 

 

 

President and Chief Executive Officer

 

 


 

EXHIBIT INDEX

 

Exhibit

Number

  

Description

 

 

 

99.1

  

Press release issued on March 8, 2017, by Catalyst Biosciences, Inc.